VEA
EWTX icon

Virtus ETF Advisers’s Edgewise Therapeutics EWTX Stock Holding History

Virtus ETF Advisers’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,526
Closed -$67.4K – 551
2024
Q4 		$67.4K Sell
2,526
-2,619
-51% -$83.4K 0.03% 402
2024
Q3 		$137K Buy
5,145
+91
+2% +$1.81K 0.06% 336
2024
Q2 		$91K Buy
+5,054
New +$88.2K 0.04% 355
2023
Q4 		– Sell
-10,384
Closed -$59.5K – 441
2023
Q3 		$59.5K Sell
10,384
-1,038
-9% -$7.06K 0.04% 404
2023
Q2 		$88.5K Sell
11,422
-1,085
-9% -$9.15K 0.05% 419
2023
Q1 		$83.4K Sell
12,507
-4,807
-28% -$44.6K 0.05% 380
2022
Q4 		$155K Sell
17,314
-155
-0.9% -$1.45K 0.08% 338
2022
Q3 		$172K Buy
17,469
+128
+0.7% +$1.29K 0.07% 333
2022
Q2 		$138K Buy
17,341
+9,212
+113% +$69.6K 0.05% 332
2022
Q1 		$79K Sell
8,129
-475
-6% -$6.11K 0.04% 341
2021
Q4 		$131K Buy
+8,604
New +$155K 0.05% 366

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Virtus ETF Advisers's EWTX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 2,526 shares — an estimated $67.4K sold.

Virtus ETF Advisers first reported a position in EWTX in Q4 2021 and held it in 11 quarters. The position peaked at $172K in Q3 2022. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,526 Edgewise Therapeutics shares in Q1 2025, an estimated $67.4K.
  • Virtus ETF Advisers first reported a position in Edgewise Therapeutics in Q4 2021 and held it in 11 quarters.
  • Virtus ETF Advisers's Edgewise Therapeutics position peaked at $172K in Q3 2022.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.